{"metadata":{"topics":["Accountability","Activism","Administrative law","Anti-corruption measures","Applied ethics","Banking","Biology","Biotechnology","Business","Business economics","Business law","Business organizations","Cash","Change","Chemical safety","Chief executive officer","Chief financial officer","Clinical medicine","Clinical research","Cognitive science","Common law","Communication","Companies","Consumer protection","Control (social and political)","Controversies","Corporate executives","Corporate finance","Corporate governance","Corporate law","Corporate personhood","Corporations","Culture","Debt","Doctor of Philosophy","Drug","Drug discovery","Drug policy","Drug safety","Drugs","Economic problems","Economics","Economics of service industries","Economies","Economy","Economy of North America","Economy of the United States","Employee relations","Employment","Employment compensation","Executive branch of the United States government","Expense","Factor income distribution","Finance","Financial economics","Financial markets","Financial problems","Financial services","Food and Drug Administration","Food and drink","Food politics","Food safety","Foodservice","Governance","Government","Government agencies","Government finances","Government information","Government institutions","Government of the United States","Government-related organizations","Great Recession","Heads of state","Health","Health agencies","Health care","Health economics","Health policy","Health research","Health sciences","Healthcare","Healthcare industry","Healthcare quality","Hierarchy","Honorifics","Human activities","Human resource management","Income statement","Industries","Information","Interpersonal relationships","Investment","Justice","Labor","Law","Leaders","Leadership","Legal fictions","Legislative branch of the United States government","Liability (financial accounting)","Life sciences","Life sciences industry","Management","Market (economics)","Medical humanities","Medical research","Medical specialties","Medical treatments","Medicinal chemistry","Medicine","Microeconomics","Money","Morality","National agencies for drug regulation","New Drug Application","North America","Patient safety","Percentage","Personal finance","Pharmaceutical industry","Pharmaceutical sciences","Pharmaceuticals policy","Pharmaceutics","Pharmacology","Pharmacy","Political activism","Political office-holders","Political science","Political titles","Politicians","Politics","Politics of the United States","Positions of authority","Presidencies","Presidencies of the United States","Presidency of the United States","President","Prevention","Private law","Product","Product safety","Products of chemical industry","Psychoactive drugs","Public administration","Public finance","Public health","Public law","Public policy","Public sphere","Quality","Restructuring","Safety","Safety organizations","Salary","Science","Science and law","Service industries","Services (economics)","Social aspects of psychoactive drugs","Social institutions","Social issues","Social policy","Tax","Taxation","Technology","Therapy","Titles","United States","United States Department of Health and Human Services agencies","United States economic policy","United States federal policy","Vice president","Virtue","Wealth","Working conditions"],"person_names":["david r. savello","dr. barrett","rieflin","ronald w. barrett","vincent j. angotti","william g. harris","william j. rieflin"],"vars":{},"organization_names":["xenoport, inc. corporate bonus plan"],"agreement_id":"be39dcfabb8d1d72ec24f7b2add32b57750c5c2cb078705d940838dab2ff5261","terms":["***David R. Savello, PhD***","***Ronald W. Barrett, PhD***","***Vincent J. Angotti***","***William G. Harris***","***William J. Rieflin***","**2010 Annual Base Salary**","**2010 Target Bonus Percentage (1)**","**Named Executive Officer Compensation Information Â– 2010 Salaries and Target Bonus Percentages**","**Named Executive Officer**","*Horizant*"]}}